# Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

> **NCT05617040** · PHASE1,PHASE2 · TERMINATED · sponsor: **Barinthus Biotherapeutics** · enrollment: 22 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** ChAdOx1-PCAQ
- **BIOLOGICAL:** MVA-PCAQ

## Key facts

- **NCT ID:** NCT05617040
- **Lead sponsor:** Barinthus Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-30
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns.
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617040, "Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05617040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*